AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 27679519
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with losartan and lisinopril
Trial: 15166558
Drug: Auricular acupuncture
RxNorm normalized name: fluocinolone
DrugBank: Fluocinolone (DB12553)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Auricular acupuncture (press needles at relaxation, tranquilizer point, and master cerebral point)
Trial: 11450179
Drug: Bupropion, sertraline,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupropion, sertraline, and venlafaxine as adjuncts to mood stabilizers
Trial: 7995315
Drug: Both written
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both written and oral information
Trial: 30325753
Drug: Antigen-specific immunotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antigen-specific immunotherapy (cancer vaccination)
Trial: 30325753
Drug: Neoadjuvant administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Neoadjuvant administration of ICI
Trial: 28450350
Drug: Rosuvastatin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin (20 mg/day) for 12 months
Trial: 17043189
Drug: Topical calcipotriene
RxNorm normalized name: calcipotriene Topical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical calcipotriene
Trial: 10934569
Drug: Intensive treatment
RxNorm normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive treatment (24.52 hours per week for one year, gradually reducing over 1 to 2 years)
Trial: 9013398
Drug: Velnacrine (10,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Velnacrine (10, 25, 50 and 75 mg t.i.d.)
Trial: 3912621
Drug: CMFVP for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CMFVP for 1 year and/or hormonal therapy (ER+ patients)
Trial: 29489066
Drug: OBE022 administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OBE022 administered after a standardized breakfast on day 1 and in the fasted state from day 3 to day 9
Trial: 25315893
Drug: 7.5% hydrogen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5% hydrogen peroxide (Oral B 3D White, Oral‐B)
Trial: 18058653
Drug: Intravenous propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous propofol alone (group P)
Trial: 18058653
Drug: Intravenous propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous propofol with oral midazolam premedication (group M + P)
Trial: 11910594
Drug: Transdermal estradiol
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal estradiol (50 micrograms per 24 hours)
Trial: 8560293
Drug: Clinic-based smoking
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinic-based smoking cessation interventions, details on dosage and duration not available
Trial: 6771931
Drug: 0.4 mg
RxNorm normalized name: biotin 0.4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg nitroglycerin perlingual application
Trial: 6771931
Drug: 0.6 mg
RxNorm normalized name: thymol 0.6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.6 mg inhalatively given isoprenalin
Trial: 25922424
Drug: 12-week individual
RxNorm normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12-week individual CBT plus 400 mg/day modafinil
Trial: 25922424
Drug: 12-week individual
RxNorm normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12-week individual CBT plus 400 mg/day modafinil (high adherent patients)
Trial: 18277886
Drug: Omeprazole maintenance
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Omeprazole maintenance therapy
Trial: 14515063
Drug: M201V [corrected]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M201V [corrected] CysLT2 receptor variant
Trial: 30506183
Drug: Local injection
RxNorm normalized name: Sclerosing agents for local injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local injection of botulinum toxin
Trial: 29415699
Drug: Adherence-supporting app
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adherence-supporting app with daily treatment reminders and electronic monitor (EM) for Cal/BD cutaneous foam.
Trial: 29415699
Drug: Adherence-supporting app
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adherence-supporting app with daily treatment reminders and EM for Cal/BD cutaneous foam.
Trial: 21878788
Drug: Short-term dynamic
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term dynamic therapy
Trial: 24884340
Drug: Cognitive therapy
RxNorm normalized name: cognitive therapy software
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive therapy and Short-term dynamic therapy
Trial: 6437840
Drug: DHM 32-550
RxNorm normalized name: DHMS
DrugBank: Dihydrostreptomycin (DB11512)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHM 32-550 (high dosage)
Trial: 6437840
Drug: DHM 32-550
RxNorm normalized name: DHMS
DrugBank: Dihydrostreptomycin (DB11512)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHM 32-550 (low dosage)
Trial: 30929188
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment arm
Trial: 25377067
Drug: Medical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical treatment to suppress all electrographic seizure activity
Trial: 25377067
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment of electroencephalographic status epilepticus
Trial: 22160383
Drug: Bortezomib-based treatment
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bortezomib-based treatment before and after autologous stem cell transplantation (arm B)
Trial: 22160383
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment without bortezomib (arm A)
Trial: 7594088
Drug: Nitroglycerin with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerin with oral hydralazine (75 mg four times a day, group II, 14 patients)
Trial: 1988576
Drug: E 50
RxNorm normalized name: Fe 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E 50 mg/m2 and prednisolone (LEP)
Trial: 1988576
Drug: E 100
RxNorm normalized name: lysine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E 100 mg/m2 and prednisolone (HEP)
Trial: 19930092
Drug: Individually tailored
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individually tailored oral health educational programme
Trial: 24372439
Drug: Standard oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard oral health educational programme
Trial: 9417158
Drug: Intravenous A1PI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous A1PI (60 mg/kg) infused on days 0, 4, 7, and 14
Trial: 7639298
Drug: Mitomycin C
RxNorm normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mitomycin C (0.2 mg/ml twice daily for five days)
Trial: 15313300
Drug: Placebo (balanced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (balanced saline solution)
Trial: 2231212
Drug: Maintenance indomethacin
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Maintenance indomethacin therapy (0.2 mg/kg/day for 5 days)
Trial: 2231212
Drug: Standard indomethacin
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard indomethacin therapy (three doses) followed by placebo (equivalent volume for 5 days)
Trial: 28762081
Drug: Previous standard-of-care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Previous standard-of-care treatments
Trial: 23856660
Drug: Nitrous oxide
RxNorm normalized name: Nitrous Oxide
DrugBank: Nitrous oxide (DB06690)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nitrous oxide plus intravenous B-vitamins
Trial: 22019968
Drug: Interferential current
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferential current therapy at 40 Hz
Trial: 22019968
Drug: Interferential current
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferential current therapy at 100 Hz
Trial: 22019968
Drug: Interferential current
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferential current therapy at 180 Hz
Trial: 22019968
Drug: Sham interferential
RxNorm normalized name: thymol
DrugBank: Thymol (DB02513)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sham interferential current therapy
Trial: 8305323
Drug: Terbinafine 1%
RxNorm normalized name: Terbinafine 1% Topical application Gel/Jelly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbinafine 1% cream (single application)
Trial: 8305323
Drug: Terbinafine 1%
RxNorm normalized name: Terbinafine 1% Topical application Gel/Jelly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbinafine 1% cream (3 days once-daily therapy)
Trial: 8305323
Drug: Terbinafine 1%
RxNorm normalized name: Terbinafine 1% Topical application Gel/Jelly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbinafine 1% cream (5 days once-daily therapy)
Trial: 8305323
Drug: Terbinafine 1%
RxNorm normalized name: Terbinafine 1% Topical application Gel/Jelly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbinafine 1% cream (7 days once-daily therapy)
Trial: 3385111
Drug: Standard trivalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard trivalent influenza vaccine (15 micrograms of B/USSR/100/83) + placebo
Trial: 3385111
Drug: Standard trivalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard trivalent vaccine (15 micrograms of B/USSR/100/83) + supplemental dose (45 micrograms of B/USSR)
Trial: 3385111
Drug: Supplemental dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplemental dose (45 micrograms of B/USSR) + placebo
Trial: 31045894
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg neostigmine/0.5 mg atropine (n = 11)
Trial: 31045894
Drug: 2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg/kg sugammadex (n = 11)
Trial: 12880604
Drug: Liquid nutrition
RxNorm normalized name: Liquid Nutrition Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid nutrition supplement
Trial: 9088996
Drug: L-asparaginase treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-asparaginase treatment (10,000 U/m2 every 3-4 days)
Trial: 9088996
Drug: E. coli
RxNorm normalized name: E. coli antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E. coli preparation Asparaginase medac (2500 U/m2)
Trial: 9088996
Drug: Erwinia preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erwinia preparation Erwinase
Trial: 2020921
Drug: Ginkgo biloba
RxNorm normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginkgo biloba extract (600 mg)
Trial: 18751626
Drug: Antenatal perineal
RxNorm normalized name: Bos taurus pineal gland preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antenatal perineal massage (10 minutes daily from 34 weeks of gestation until delivery)
Trial: 16916298
Drug: Homapak (fixed-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Homapak (fixed-dose CQ+S/P combination)
Trial: 16916298
Drug: GMP made
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GMP made drugs
Trial: 10704627
Drug: Oral estradiol
RxNorm normalized name: estradiol Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral estradiol (E2) valerate, 2 mg/day
Trial: 10704627
Drug: Transdermal E2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal E2 gel, 1 mg/day
Trial: 24259265
Drug: Capsaicin 8%
RxNorm normalized name: CAPSAICIN 8% PATCH KIT,4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsaicin 8% cutaneous patch
Trial: 15181577
Drug: Quadrivalent human/bovine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadrivalent human/bovine reassortant rotavirus vaccine
Trial: 11434846
Drug: Otikon Otic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Otikon Otic Solution (naturopathic herbal extract)
Trial: 8281886
Drug: Low-fat diet
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-fat diet and physical training (1 h twice weekly and daily bicycle ergometry for 30 min)
Trial: 2815173
Drug: Systemic metronidazole
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Systemic metronidazole therapy
Trial: 2815173
Drug: Mechanical local
RxNorm normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mechanical local therapy
Trial: 31199291
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as Usual plus Videoconferencing (TAU-VC)
Trial: 28495863
Drug: Soluble urokinase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soluble urokinase plasminogen activator receptor >11,633 pg/ml (third tertile)
Trial: 28495863
Drug: Addition of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Addition of soluble urokinase plasminogen activator receptor to a risk factor model
Trial: 25400106
Drug: 0% L-arabinose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0% L-arabinose in meal A (sucrose and starch from wheat flour)
Trial: 25400106
Drug: 5% L-arabinose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% L-arabinose in meal A (sucrose and starch from wheat flour)
Trial: 25400106
Drug: 10% L-arabinose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% L-arabinose in meal A (sucrose and starch from wheat flour)
Trial: 25400106
Drug: 0% L-arabinose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0% L-arabinose in meal B (starch from wheat flour)
Trial: 25400106
Drug: 20% L-arabinose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20% L-arabinose in meal B (starch from wheat flour)
Trial: 25400106
Drug: Liquid meal
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid meal with maltose and 0% L-arabinose
Trial: 25400106
Drug: Liquid meal
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid meal with maltose and 20% L-arabinose
Trial: 21199857
Drug: 1-dose varicella
RxNorm normalized name: VARICELLA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-dose varicella vaccination
Trial: 16458964
Drug: Fixed-combination latanoprost-timolol
RxNorm normalized name: latanoprost / timolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-combination latanoprost-timolol
Trial: 14769716
Drug: Potassium chloride
RxNorm normalized name: Potassium Chloride
DrugBank: Potassium chloride (DB00761)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Potassium chloride pills (medication)
Trial: 8406350
Drug: 5 MU
RxNorm normalized name: MULTISTIX 5 MULTIPLE TEST STRIP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 MU interferon-alpha 2b (in combination with GM-CSF)
Trial: 2446054
Drug: Ketanserin (20‐80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketanserin (20‐80 mg daily)
Trial: 2446054
Drug: Alpha-methyldopa (500‐2000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha-methyldopa (500‐2000 mg daily)
Trial: 31839432
Drug: TPF induction
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TPF induction chemotherapy in normal BMI and clinical stage IVA disease
Trial: 24001888
Drug: Intravenous golimumab
RxNorm normalized name: Golimumab
DrugBank: Golimumab (DB06674)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous golimumab 2 mg/kg + methotrexate (MTX)
Trial: 25224125
Drug: neuro-music therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: neuro-music therapy (counseling plus eight 50-minute sessions of individualized music therapy)
Trial: 19191657
Drug: Boosted protease
RxNorm normalized name: protease
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Boosted protease inhibitor therapy (control)
Trial: 16846509
Drug: Extended care
RxNorm normalized name: ALCOHOL 0.7 mL in 1 mL TOPICAL LIQUID [EXTENDED CARE Foaming Hand Sanitizer]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended care treatment groups
Trial: 9229195
Drug: Acipimox (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acipimox (250 mg, twice daily)
Trial: 8250301
Drug: Alfentanil (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfentanil (both doses)
Trial: 1994667
Drug: Pindolol (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pindolol (10 mg twice daily)
Trial: 27389975
Drug: ABT-494 (3,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-494 (3, 6, 12, or 18 mg twice daily)
Trial: 27389975
Drug: ABT-494 (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-494 (12 and 18 mg)
Trial: 27389975
Drug: ABT-494 (6-18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-494 (6-18 mg)
Trial: 20582466
Drug: Pq1wC (paclitaxel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pq1wC (paclitaxel 60 mg/m(2) days 1, 8, 15, carboplatin AUC 6 day 1 for every 3 weeks)
Trial: 20582466
Drug: Pq3wC (paclitaxel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pq3wC (paclitaxel 175 mg/m(2) day 1, carboplatin AUC 6 d1, every 3 weeks)
Trial: 18618000
Drug: AA versus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AA versus CC diplotype frequency
Trial: 12061945
Drug: riluzole 100
RxNorm normalized name: Riluzole
DrugBank: Riluzole (DB00740)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: riluzole 100 mg/day (50 mg b.i.d.)
Trial: 11956263
Drug: Concurrent cisplatin‐RT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent cisplatin‐RT (CRT) - cisplatin 40 mg/m² weekly for up to 8 weeks with radical RT
Trial: 11956263
Drug: Concurrent cisplatin‐RT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent cisplatin‐RT (CRT)
Trial: 7978475
Drug: TTSF-75 patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TTSF-75 patch (75 micrograms/h)
Trial: 7978475
Drug: TTSF-50 patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TTSF-50 patch (50 micrograms/h)
Trial: 7978475
Drug: TTSF-50 and
RxNorm normalized name: ivacaftor
DrugBank: Ivacaftor (DB08820)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: TTSF-50 and TTSF-75 patches
Trial: 7978475
Drug: TTSF patches
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TTSF patches
Trial: 7978475
Drug: TTSF-75 patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TTSF-75 patch
Trial: 3173046
Drug: Naloxone (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (2 mg)
Trial: 31812719
Drug: 5 Gy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 Gy × 5 fractions of precision radiation therapy
Trial: 25497513
Drug: Intensive blood
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive blood pressure lowering treatment (target SBP <140 mmHg within 1 hour)
Trial: 25497513
Drug: Guideline‐recommended blood
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guideline‐recommended blood pressure lowering treatment (target SBP <180 mmHg)
Trial: 21790298
Drug: Medikinet retard
RxNorm normalized name: Percy Medicine
DrugBank: Bismuth subsalicylate (DB01294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medikinet retard (lower daily dose, similar IR components in the morning)
Trial: 11204897
Drug: Alcohol (0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol (0.6 g/kg for males and 0.5 g/kg for females)
Trial: 22502839
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group without TEAS treatment (n=39)
Trial: 17361105
Drug: HSP90 inhibitor
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: HSP90 inhibitor 17-allylaminogeldanamycin
Trial: 11899948
Drug: Tibolone 2.5
RxNorm normalized name: tibolone 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tibolone 2.5 mg after a high-fat meal
Trial: 11899948
Drug: Tibolone 2.5
RxNorm normalized name: tibolone 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tibolone 2.5 mg after fasting
Trial: 7341547
Drug: d,1-Carnitine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d,1-Carnitine (3 g/daily)
Trial: 30308560
Drug: AAV2-REP1 gene
RxNorm normalized name: Recombinant adeno-associated virus retinal pigment epithelium gene vector AAV2-hRPE65v2
DrugBank: Voretigene neparvovec (DB13932)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AAV2-REP1 gene therapy (0.1-mL subretinal injection of 10 genome particles)
Trial: 31465092
Drug: AAV2-REP1 gene
RxNorm normalized name: Recombinant adeno-associated virus retinal pigment epithelium gene vector AAV2-hRPE65v2
DrugBank: Voretigene neparvovec (DB13932)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AAV2-REP1 gene therapy
Trial: 25154896
Drug: 6.4% glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6.4% glucose (CHO) solution
Trial: 17606839
Drug: Bendroflumethiazide 5
RxNorm normalized name: bendroflumethiazide 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bendroflumethiazide 5 mg
Trial: 17606839
Drug: Amiloride 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiloride 40 mg
Trial: 7784236
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy plus prednisone